Đang chuẩn bị liên kết để tải về tài liệu:
Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: A prospective, multicenter clinical trial protocol

Currently, adjuvant therapy is not recommended for patients with thoracic esophageal squamous cell cancer (TESCC) after radical surgery, and a proportion of these patients go on to develop locoregional recurrence (LRR) within 2 years. Besides, there is no evidence for salvage chemoradiation therapy (CRT) in patients with residual tumor after esophagectomy (R1/R2 resection). |